Holen Sie sich die Stockscreener-App
23.52
2.98%
0.6821
Schlusskurs vom Vortag:
$22.84
Offen:
$22.99
24-Stunden-Volumen:
438.75K
Relative Volume:
0.39
Marktkapitalisierung:
$2.06B
Einnahmen:
$23.38M
Nettoeinkommen (Verlust:
$-155.22M
KGV:
-10.74
EPS:
-2.19
Netto-Cashflow:
$-134.36M
1W Leistung:
-2.48%
1M Leistung:
+4.63%
6M Leistung:
+7.16%
1J Leistung:
-37.41%
1-Tages-Spanne:
$22.82
$23.63
1-Wochen-Bereich:
$22.09
$24.07
52-Wochen-Spanne:
$13.45
$40.74
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Firmenname
Ideaya Biosciences Inc
Sektor
Branche
Telefon
650-443-6209
Adresse
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Vergleichen Sie IDYA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
23.53 | 2.02B | 23.38M | -155.22M | -134.36M | -2.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
386.27 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.64 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.94 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
638.65 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
287.85 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-22 | Eingeleitet | TD Cowen | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2025-06-26 | Eingeleitet | Wells Fargo | Overweight |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-11-05 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-07-08 | Eingeleitet | Mizuho | Outperform |
| 2024-03-08 | Eingeleitet | BTIG Research | Buy |
| 2023-08-08 | Eingeleitet | SVB Securities | Outperform |
| 2023-05-24 | Eingeleitet | Goldman | Buy |
| 2023-04-24 | Hochstufung | Stifel | Hold → Buy |
| 2023-03-23 | Eingeleitet | Berenberg | Buy |
| 2023-02-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-12-28 | Eingeleitet | CapitalOne | Overweight |
| 2022-10-27 | Eingeleitet | Citigroup | Buy |
| 2022-08-15 | Herabstufung | Stifel | Buy → Hold |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-03-10 | Hochstufung | Stifel | Hold → Buy |
| 2021-09-23 | Eingeleitet | Stifel | Hold |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-03-11 | Eingeleitet | Guggenheim | Buy |
| 2020-10-07 | Eingeleitet | Wedbush | Outperform |
| 2020-09-01 | Eingeleitet | Northland Capital | Outperform |
| 2020-07-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-06-17 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-13 | Eingeleitet | ROTH Capital | Buy |
| 2019-10-17 | Eingeleitet | Oppenheimer | Outperform |
| 2019-09-10 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-06-17 | Eingeleitet | Citigroup | Buy |
| 2019-06-17 | Eingeleitet | JP Morgan | Neutral |
| 2019-06-17 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Ideaya Biosciences Inc Aktie (IDYA) Neueste Nachrichten
How to use a screener to detect IDEAYA Biosciences Inc. breakoutsBuy Strategy Tracker with Growth Indicators - Newser
Analyzing net buyer seller activity in IDEAYA Biosciences Inc.Ten-Year Sector Performance and Summary Analysis - Newser
How sentiment analysis helps forecast IDEAYA Biosciences Inc.Risk Shielded Trade Watch with Analysis - Newser
Leerink Partnrs Has Bullish Estimate for IDYA Q3 Earnings - Defense World
Has IDEAYA Biosciences Inc. found a price floorFree Entry Zone Strategy for Consistent Profit - Newser
Cantor Fitzgerald Issues Negative Forecast for IDYA Earnings - Defense World
Will IDEAYA Biosciences Inc. outperform the marketLow Volatility Stock Analysis With Confidence - Newser
Is a relief rally coming for IDEAYA Biosciences Inc. holdersTen-Year Sector Performance and Summary Analysis - Newser
GSK and Ideaya’s Promising Study on Solid Tumors: A Potential Game-Changer? - TipRanks
IDEAYA Biosciences: Hold Rating Amid Key Pipeline Developments and Anticipated Clinical Milestones - TipRanks
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $48.09 Average PT from Analysts - Defense World
Wedbush Predicts Increased Earnings for IDEAYA Biosciences - Defense World
RBC Capital Initiates IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $30 - 富途牛牛
Ideaya Biosciences, Hengrui announce oral presentation at IASLC 2025 - MSN
Risk vs reward if holding onto IDEAYA Biosciences Inc.Free Early Breakout Entry Point Notifications - Newser
IDEAYA Biosciences Inc Reports Q2 2025 Financial Results: Net Loss of $77.5 Million, EPS of -$0.88, and No Revenue - AInvest
Ideaya Biosciences Q2 EPS Beats Consensus, Sees Catalyst-Rich Period Ahead - AInvest
GSK and Ideaya’s Promising Study on Tumor-Reducing Drug GSK4418959 - TipRanks
Chart based analysis of IDEAYA Biosciences Inc. trendsPredictive Model for Intraday Swing Forecast - Newser
Ideaya Biosciences shares rise 3.19% premarket after reporting Q2 net loss and positive trial data. - AInvest
IDEAYA Biosciences Reports Q2 2025 Financial Results - TipRanks
IDEAYA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update - The Malaysian Reserve
IDEAYA (IDYA) Q2 Net Loss Improves 27% - The Motley Fool
IDEAYA (IDYA) Q2 Net Loss Improves 27% - Nasdaq
IDEAYA Biosciences Enters ADC Market with Solid Tumor Focus - AInvest
IDEAYA Biosciences: Moving Into ADCs For Solid Tumors (NASDAQ:IDYA) - Seeking Alpha
Ideaya Biosciences earnings missed by $0.09, revenue topped estimates - Investing.com
IDEAYA Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
IDEAYA Biosciences Reports Q2 GAAP EPS of -$0.88, Misses Expectations - AInvest
IDEAYA Biosciences's Q2 net loss widens as costs mount - MarketScreener
IDEAYA Reports Phase 2/3 Trial Data and Neoadjuvant Darovasertib Results - AInvest
IDEAYA Advances 6 Clinical Programs, Reports Massive $992M Cash Runway Through 2029 - Stock Titan
Published on: 2025-08-05 04:17:11 - metal.it
Ideaya Biosciences Advances in Ocular Melanoma Treatment with Darovasertib Study - TipRanks
Ideaya Biosciences shares rise 6.02% premarket as New Zealand shares down tracking Wall Street sell-off. - AInvest
What institutional investors are buying IDEAYA Biosciences Inc. stockCapitalize on proven trading setups - Jammu Links News
How many analysts rate IDEAYA Biosciences Inc. as a “Buy”Maximize portfolio growth with expert advice - Jammu Links News
How does IDEAYA Biosciences Inc. compare to its industry peersConsistent triple-digit returns - Jammu Links News
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - cnhinews.com
What analysts say about IDEAYA Biosciences Inc. stockGet expert advice on portfolio optimization - Jammu Links News
Should I hold or sell IDEAYA Biosciences Inc. stock in 2025Unlock powerful portfolio management tools - Jammu Links News
What makes IDEAYA Biosciences Inc. stock price move sharplyInvest smarter with daily market updates - Jammu Links News
What drives IDEAYA Biosciences Inc. stock priceMaximize gains with strategic stock entries - Jammu Links News
What is the risk reward ratio of investing in IDEAYA Biosciences Inc. stockGet alerts on the hottest stocks daily - Jammu Links News
How strong is IDEAYA Biosciences Inc. company’s balance sheetMarket-crushing stock picks - Jammu Links News
What catalysts could drive IDEAYA Biosciences Inc. stock higher in 2025Unlock expert stock analysis and alerts - Jammu Links News
IDEAYA Biosciences Awards Stock Options to New Employee - AInvest
Historical volatility pattern of IDEAYA Biosciences Inc. visualizedIntraday Signal Forecast for Fast Traders - Newser
IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
IDEAYA Biosciences Awards $765K Worth of Stock Options to New Employee: Full Grant Details - Stock Titan
How to build a custom watchlist for IDEAYA Biosciences Inc.Consistent Gain Plan with AI Support - Newser
Finanzdaten der Ideaya Biosciences Inc-Aktie (IDYA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.77%
2.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):